Overview

DTaP-IPV manufactured by GlaxoSmithKline as Kinrix and Sanofi Pasteur as Quadracel have the same CVX of 130 but different dosing recommendations. Refer to the chart below for detail information of vaccine dosing.

Kinrix: A combination of DTaP and IPV vaccine. 

• It is approved for use as the fifth dose of DTaP and the fourth dose of IPV in children ages 4 through 6 years
• Used for children who received DTaP (Infanrix) and/or DTaP-HepB-IPV (Pediarix) as the first three doses and DTaP (Infanrix) as the fourth dose.

Quadracel: A combination of DTaP and IPV vaccine. 

• It was approved by the FDA in 2015 for use in children ages 4 through 6 years of age as the fifth dose in the DTaP series and as the fourth or fifth dose in the IPV series.
• Used for children who received 4 doses of Pentacel (DTaP-IPV-Hib) and/or Daptacel (DTaP+) vaccine.

Vaccine Guidance:

• Should not be given to infants younger than 6 weeks of age or to children 7 years or older.
• Should not be used for any dose greater than the first 3 doses of DTaP.
• HepB dose 3 should be administered at least 8 weeks after HepB dose 2 and at least 16 weeks after HepB dose 1.
• HepB dose 3 should not be administered before 24 weeks of age.

Vaccine Guidance:

• Should not be used for any dose in the primary series for children age 5 years or older or as the booster dose for children ages 4 - 6 years.
• If you discover historically this was given to a 5+ year old, the DTaP and IPV doses are still considered "valid" and this would be considered an "off label use" but would not need to be repeated.
• The minimum recommended interval between DTaP dose 3 and DTaP dose 4 is 6 months. However, DTaP dose 4 need not be repeated if administered at least 4 months after DTaP dose 3.
• There is a special grace period of 2 months, for the above guidance, which can be used when evaluating records retrospectively. An additional 4 days should not be added to this grace period prospectively but can be added retrospectively.

Kinrix should be used when:

• Received DTaP (Infanrix) doses 1 through 4
• OR when received DTaP-HepB-IPV (Pediarix) doses 1 through 3 plus DTaP (Infanrix) as dose 4

Vaccine Guidance:

• Kinrix should not be given to children younger than age 4 years.
• In review of historic vaccines, you can count the vaccine as a valid dose of DTaP and IPV when:
  • The minimum interval between administering dose 3 and dose 4 of DTaP is 6 months
  • The minimum interval between administering dose 2 and dose 3 of IPV is 4 weeks.

Quadracel should be used when:

• Received DTaP+ (Daptacel) and/or DTaP-IPV-Hib (Pentacel) doses 1 through 4.

Vaccine Guidance:

• Quadracel should not be given to children younger than age 4 years.